News - Merck KGaA, Erbitux

Filter

Current filters:

Merck KGaAErbitux

Popular Filters

Merck Serono’s Erbitux to be funded by CDF in England for mCRC

28-02-2014

The UK’s Cancer Drugs Fund (CDF) says that Erbitux (cetuximab) can be used in the first line setting…

ErbituxFinancialHealthcareMerck KGaAMerck SeronoNorthern EuropeOncologyPharmaceuticalUK

European Commission backs wider use of Merck’s Erbitux

European Commission backs wider use of Merck’s Erbitux

24-12-2013

Merck Serono, the biopharmaceutical division of Germany’s Merck KGaA, has gained European Commission…

ErbituxEuropeMerck KGaAMerck SeronoOncologyPharmaceuticalRegulation

Merck KGaA improves guidance with strong third quarter results

Merck KGaA improves guidance with strong third quarter results

14-11-2013

Germany’s Merck KGaA (MRK: DE) has posted solid organic revenue growth of 4.7% for the third quarter…

BiotechnologyErbituxEuropeFinancialMerck KGaAMerck SeronoPharmaceuticalRebif

Highlights from European Cancer Congress on Kadcyla, Yervoy, Erbitux and Somatuline

30-09-2013

A host of new oncology data was presented at the European Cancer Congress in Amsterdam, the Netherlands,…

Bristol-Myers SquibbErbituxEuropeIpsenKadcylaMerck KGaAOncologyPharmaceuticalResearchRocheSomatulineYervoy

Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux

23-05-2013

Australian drug developer Alchemia (ASX: ACL) and Merck Serono, a subsidiary of Germany's Merck KGaA…

AlchemiaBiotechnologyErbituxHA-IrinotecanMerck KGaAMerck SeronoOncologyPharmaceuticalResearch

News briefs from Threshold, Merck KGaA and GSK

18-09-2012

US biotech firm Threshold Pharmaceuticals (Nasdaq: THLD) said yesterday that data from a Phase IIb trial…

BiotechnologyErbituxEuropeGlaxoSmithKlineMerck KGaAMerck SeronoOncologyPharmaceuticalRegulationResearchSynflorixTH-302Threshold PharmaceuticalsVaccines

News briefs from Merck KGaA and Sanofi

05-07-2012

German drug major Merck KGaA )MRK: DE) revealed this morning that its Phase III EXPAND trial, which assessed…

cilengitideErbituxManagementMerck KGaAMergers & AcquisitionsPharmaceuticalResearchSanofi

Adding cetuximab following colon cancer surgery does not improve disease-free survival

04-04-2012

Adding the drug cetuximab, the active ingredient of Erbitux from German drug major Merck KGaA (MRK: DE),…

cetuximabErbituxMerck KGaAOncologyPharmaceuticalResearch

Chinese colorectal cancer drug market forecast to grow to over $400 million in 2016

04-04-2012

The colorectal cancer drug market in China will grow from a value of $261 million in 2011 to $404 million…

Asia-PacificAvastinErbituxMarkets & MarketingMerck KGaAOncologyPharmaceuticalRoche

UK’s NICE negative draft guidance for metastatic colorectal cancer drugs Erbitux, Avastin and Vectibix

06-09-2011

In new draft guidance issued this week, UK drug watchdog the National Institute for Health and Clinical…

AmgenAvastinErbituxEuropeMerck KGaAOncologyPharmaceuticalPricingRegulationRocheVectibix

Erbitux and Gilenya added to Australia’s PBS listing

02-09-2011

More than 400,000 Australians will benefit from new subsidized medicines, effective September 1, as Minister…

Asia-PacificErbituxGilenyaMerck KGaANeurologicalNovartisOncologyPharmaceuticalPricingRegulation

Back to top